We find that NSD3 expression is strongly associated with clinical prognosis in pancreatic cancer, with genetic amplification of NSD3, low levels of NSD3 promoter methylation and immune cell infiltration to tumor sites as correlated features. This evidence concerns the gene NSD3 and familial pancreatic carcinoma.